We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Locus Announces Focus on Drug Discovery Collaboration Business, Branded as Ansaris

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Locus Pharmaceuticals has announced that in conjunction with a transformation to a drug discovery collaboration business model, it has created a new division, Ansaris, which will include most of its operations and personnel.

Ansaris was formed to leverage the strengths and fully realize the value of Locus’ drug discovery computational platform and 10 years’ experience in integrated drug design, discovery, and development. Ansaris establishes collaborations and partnerships with companies seeking innovative solutions to drug design challenges.

"We adopted the name Ansaris to symbolize our differentiated approach to drug discovery, leveraging our demonstrated expertise in computational chemistry, medicinal chemistry, and our unique fragment-based drug discovery technology platform,” said Joan Lau, President of Ansaris.

“The strength of the Ansaris discovery process lies not just with the technology, but also the integrated drug design team approach, uniquely customized for each project. We have effectively utilized our capabilities to deliver novel chemotypes for challenging targets for our internal pipeline, and now we will direct our successful discovery model toward delivering innovative preclinical candidates for our collaboration partners.”